



**Name of Clinical Care Pathway**

Primary Sclerosing Cholangitis (PSC)

**Objective**

Provide direction regarding the screening, management and follow-up for patients with primary sclerosing cholangitis (PSC)

**Patient Population**

Adult patients ( $\geq 18$  years) with a possible or established diagnosis of PSC

Alex Frolkis, MD (University of Calgary)  
Aldo J. Montano-Loza, MD, MSc, PhD, FAASLD, FACG (University of Alberta)

*These clinical decision support tools were developed by Canadian experts in primary sclerosing cholangitis, based on their interpretation of current evidence and considerations specific to Canadian healthcare. International guidelines from Europe and the United States are available. However, these may reflect regional factors that might not directly be applicable in Canada.*

## Abbreviations

AIH	Autoimmune hepatitis
ALP	Alkaline phosphatase
AST	Aspartate aminotransferase
Ca 19.9	Carbohydrate antigen 19-9
CCA	Cholangiocarcinoma
DEXA	Dual-energy X-ray absorptiometry
ERC	Endoscopic retrograde cholangiography
GGT	$\gamma$ -glutamyl transferase
Hb	Hemoglobin
HbA1c	Hemoglobin A1c
HCC	Hepatocellular carcinoma
IBD	Inflammatory bowel disease
IgG4	Immunoglobulin G4
INR	International normalized ratio
LFTs	Liver function tests
LSM	Liver stiffness measurement
LT	Liver transplant (or transplantation)
MELD	Model for end-stage liver disease
MRC	Magnetic resonance cholangiography
MRCP	Magnetic resonance cholangiopancreatography
MRI	Magnetic resonance imaging
MRS	Mayo risk score
PSC	Primary sclerosing cholangitis
TB	Total bilirubin
UC	Ulcerative colitis
UDCA	Ursodeoxycholic acid
ULN	Upper limit of normal
VCTE	Vibration-controlled transient elastography

## Highlight Box

- Patients with inflammatory bowel disease (IBD) should have routine liver function tests, and those with chronic cholestasis (ALP > 1.5 X ULN) should be investigated for PSC with magnetic resonance cholangiography (MRC).
- Approximately 60% to 80% of people with primary sclerosing cholangitis (PSC) also have IBD, most often ulcerative colitis. Patients might be asymptomatic at diagnosis, which often occurs in their 30s or 40s after routine blood tests show abnormal liver function.
- PSC progresses slowly and unpredictably and increases the risk of cholangiocarcinoma, gallbladder cancer, and, in patients with coexisting IBD, colorectal cancer.
- Patients with high-grade strictures defined as biliary stenosis on MRC with >75% reduction of duct diameter in the common bile duct or hepatic ducts warrant further endoscopic investigation, and those with relevant stricture (cholangitis, pruritus) warrants endoscopic balloon dilation.
- Currently, there is no medical treatment proven to stop or slow the progression of PSC; a liver transplant is the only curative option for advanced disease and liver failure.

## Introduction

Primary sclerosing cholangitis (PSC) is a rare chronic bile duct disease, characterized by multifocal bile duct strictures and progressive liver disease. The current incidence is 0.87 per 100 000 and prevalence 13.53 per 100 000, and it can affect all age groups and both sexes, but is more common in men (>70%). The median age at diagnosis is 30 to 40 years. Inflammatory bowel disease coexists in most patients (~70%), mainly ulcerative colitis (UC).

A major challenge in the clinical management of PSC is a highly increased and unpredictable risk of hepatobiliary and colonic malignancy.

## Diagnosis

The diagnosis of PSC is frequently incidental, with 50% of patients being asymptomatic; however, after 5 years of diagnosis, 20% of asymptomatic patients develop clinical symptoms, and 75% exhibit evidence of disease progression, as indicated by biochemical or radiographic changes. The most frequent symptoms are fatigue, abdominal pain, jaundice, pruritus, and fever.

The presence of symptoms has clinical significance, as patients with symptoms at diagnosis have a median survival until death or liver transplant of 9 years, compared to 12-22 years in all patients with PSC.

### How is PSC diagnosed in adults?

In adult patients presenting with elevated serum markers of cholestasis, a diagnosis of large duct PSC should be made in the presence of typical findings of sclerosing cholangitis on high-quality cholangiography and after exclusion of secondary causes. The preferred diagnostic test is magnetic resonance cholangiography (MRC). A diagnosis of small duct PSC should be considered in patients with elevated serum markers of cholestasis of unknown cause, normal high-quality cholangiography, and compatible histology of PSC, particularly in those with concomitant inflammatory bowel disease (IBD). Autoantibodies should not be used to diagnose or risk-stratify people with PSC.


PSC has been broadly classified into **large-duct PSC** and **small-duct PSC**, with large-duct PSCs being further subdivided into extrahepatic disease involving the common ducts or first-order ducts and intrahepatic disease involving second-order and third-order branches.

Patients affected with either form of PSC might present very differently. While many patients with large-duct PSC will present with the classic cholestatic laboratory findings of elevated alkaline phosphatase (ALP) and an abnormal cholangiogram, others can have an atypical presentation that can lead to delays in diagnosis.

The foundation of PSC diagnosis is a magnetic resonance cholangiography (MRC) or endoscopic retrograde cholangiography (ERC) that detects bile duct changes with multifocal strictures or segmental dilatations in the intrahepatic or extrahepatic biliary tree. Patients with small-duct PSC should have had a normal cholangiogram within the preceding year. Small-duct PSC is generally thought to represent an earlier stage of PSC, with rates of progression to large-duct PSC of 33 to 55% reported in observational studies.

# crohn's colitis

**Flowchart 1: International Primary Sclerosing Cholangitis study group diagnostic criteria for PSC (Adapted from Manns MP et al.)**



Diagnosis of PSC requires assessment of multiple clinical components. In 2021, the International PSC Study Group published their diagnostic criteria for PSC. These criteria initially categorize patients according to the bile duct changes observed with MRC or ERC. Other supportive criteria include histological findings if liver biopsy has been performed, elevated ALP and diagnosis of IBD. By combining the assessment of these criteria, patients can then be categorized into definite large-duct PSC, probable large-duct PSC or small-duct PSC (Flowchart 1).

For details on differentiating IgG4-SC from PSC, see the Supplementary Resources section.

## Prognosis

Approaches to simple risk stratification of PSC at initial work-up using non-invasive tools.

### “Low risk” of events:


- Small duct PSC and no evidence of cirrhosis
- Classical PSC and (all to be present): asymptomatic with normal bilirubin, albumin, platelets, and INR, ALP <1.5 ULN
- LSM (VCTE) <6.5 kPa, limited biliary changes on MRI/MRCP

### “Significant risk” of events, if any present:

- Symptomatic
- ALP >1.5 ULN, abnormal bilirubin, albumin, platelets or INR

LSM (VCTE) >9.9 kPa, extensive biliary changes (especially intrahepatic biliary dilatation) on MRI/MRCP

### Flowchart 2: PSC risk stratification



Risk stratification should be performed at diagnosis of PSC be revisited over time. Variables associated with low risk for disease progression include low ALP, normal total bilirubin level and early-stage fibrosis. For patients at such low risk, monitoring laboratory tests every 6–12 months and repeating non-invasive fibrosis assessment with liver stiffness measurement (LSM) every 2–3 years is recommended.

By contrast, patients with elevated ALP levels, elevated bilirubin and/or increased liver stiffness are at high risk for progression to cirrhosis, clinical liver decompensation, liver transplant or death. Liver chemistries of these patients should be monitored every 3–6 months and liver stiffness be rechecked annually.

In addition, they would benefit from a trial of treatment with ursodeoxycholic acid (UDCA) or consideration for clinical trial participation. If UDCA is initiated, response to therapy should be assessed in 6–12 months based on symptoms and laboratory tests. If significant improvement is not observed, the drug should be discontinued.

Validated prognostic models are summarized in Supplementary Table S1.

## Medical treatment

There is no effective medical treatment. Ursodeoxycholic acid (UDCA) at doses of 15 mg/kg/d can be given since it may improve serum liver tests and surrogate markers of prognosis; however, available data do not allow for a firmer recommendation. UDCA at doses of 28-30 mg/kg/d **should not be given**.

A multicentric study was stopped early since UDCA at high dose (28 to 30 mg/kg/day) increased the risk of disease progression and worse outcomes, defined as cirrhosis development, varices, CCA, LT, or death, mainly in patients with early-stage.

In addition, high-dose UDCA was also associated with an increased risk of colorectal neoplasias among patients with UC.

Long-term use of antibiotics is not recommended for the treatment of PSC in the absence of recurrent bacterial cholangitis.

## High-grade strictures in PSC

In PSC, high-grade strictures, previously known as dominant strictures, develop in a significant portion of patients, ranging from 36% to 56%.

These strictures, which are narrowed areas in the bile ducts, can lead to impaired bile drainage, causing symptoms like jaundice, pruritus, and recurrent cholangitis.


## Recommendations:

### Abandon the term “Dominant stricture”

**High-grade stricture:** A biliary stricture on MRI/MRCP with >75% reduction of duct diameter in the common bile duct or hepatic ducts. This warrants diagnostic work-up, with endoscopic retrograde cholangiopancreatography (ERCP), with brush cytology, or cholangioscopy with targeted directed biopsies if available (Refer to Figure 1).

**Relevant stricture:** A high-grade biliary stricture on imaging in the common bile duct or hepatic ducts with signs or symptoms of obstructive cholestasis and/or bacterial cholangitis, warrants endoscopic therapy with balloon dilation.


# crohn's colitis




**Figure 1: High-grade biliary strictures in primary sclerosing cholangitis.**

Diagram and imaging examples showing >75% reduction in duct diameter involving the hepatic ducts (top) and the common bile duct (bottom). Adapted from Fung BM et al., 2019

Flowchart 3.0: PSC screening for high-grade strictures



Flowchart 3.1: Recommendations if high-grade strictures are identified



\*Use cholangioscopy where available or ERCP remains acceptable.

## Suggested algorithm for follow-up in PSC

### Routine surveillance

Regular surveillance in patients with PSC is essential for the early detection of disease progression and associated malignancies, including cholangiocarcinoma, gallbladder carcinoma, and colorectal cancer. Early identification through structured monitoring can significantly impact management decisions and long-term outcomes.

#### Every 12 months for all, every 6 months for patients with high risk.

- Serum liver tests
- Clinical evaluation
- Every 12 months (even in patients with low risk)
- MRC
- US with special attention to gallbladder wall abnormalities. Gallbladder polyps of >8 mm is an indication for cholecystectomy, as it can lead to gallbladder cancer in PSC, and <8 mm warrants a close follow-up with US (3-6 months).
- Colonoscopy (Every 5 years in those without IBD at initial staging). If IBD is present, a colonoscopy should be done annually in accordance with Dysplasia CCP. Refer to the CCP here: [Colon Dysplasia Surveillance](#).
- LSM by VCTE (Every 2 to 4 years)
- Assessment of bone mineral density is recommended for all individuals with PSC at the time of diagnosis, using dual-energy X-ray absorptiometry (DEXA). Follow-up and treatment of osteopenia and osteoporosis should follow the current practice guidelines.
- Vitamin D levels.

#### Additional workup when clinically indicated (new symptoms or new or worsening abnormalities in routine investigations, i.e. increasing ALP or bilirubin)

- Suspected CCA: Ca 19.9 and MRC.
- Suspected AIH or drug toxicity (autoantibodies, liver biopsy).
- Suspected clinically significant portal hypertension (Baveno VII criteria): gastroscopy, non-selective beta blockers.

#### How should pruritus be managed in people with PSC?

- Exclude relevant bile duct strictures in PSC.
- If present and reachable, relevant strictures should be treated by endoscopic balloon dilatation.

Table 1: Pharmacological treatment of moderate to severe pruritus

Evidence	Drug	Potential side effect
1 <sup>st</sup> line	Bezafibrate (400 mg daily)	Renal insufficiency, myalgia, myopathy, hepatitis
2 <sup>nd</sup> line	Rifampicin (150-300 mg/d)	Hepatitis
3 <sup>rd</sup> line	Naltrexone (12.5-50 mg/d)	Opioid withdrawal syndrome
No evidence for PSC	Anion exchange resins (cholestyramine [4 g once to four times daily])	Abdominal discomfort
No evidence for PSC	Sertraline (50-75 mg/d)	

### Liver transplantation for PSC

Patients with PSC should be referred for LT when they develop any of the complications listed below:

- Patients progressing to decompensated cirrhosis
- MELD score  $\geq 15$
- HCC meeting transplant criteria

Other indications for LT include:

- Intractable pruritus
- Recurrent bacterial cholangitis
- High-grade dysplasia (in some LT centers)
- Hilar CCA (Radial mass  $< 3$  cm, in selected Canadian LT centers, Alberta, Montreal and Toronto).



## Resources for Patients

PSC Partners Canada: <https://pscpartners.ca/resource/lessons-learned-post-liver-transplant/>

## Resources for Providers

EASL Clinical Practice Guidelines on sclerosing cholangitis: [https://www.journal-of-hepatology.eu/article/S0168-8278\(22\)00326-9/fulltext](https://www.journal-of-hepatology.eu/article/S0168-8278(22)00326-9/fulltext)

## References

de Vries E, Bolier R, Goet J, Parés A, Verbeek J, de Vree M, Drenth J, van Erpecum K, van Nieuwkerk K, van der Heide F, Mostafavi N, Helder J, Ponsioen C, Oude Elferink R, van Buuren H, Beuers U; Netherlands Association for the Study of the Liver-Cholestasis Working Group. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: a double-blind, randomized, placebo-controlled trial. *Gastroenterology*. 2021;160(3):734-743.e6. <https://doi.org/10.1053/j.gastro.2020.10.001>

Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. *Am J Gastroenterol*. 2011;106(9):1638-1645. <https://doi.org/10.1038/ajg.2011.156>

Ebadi M, Rider E, Tsai C, Wang S, Lytvyak E, Mason A, Montano-Loza AJ. Prognostic significance of severe vitamin D deficiency in patients with primary sclerosing cholangitis. *Nutrients*. 2023;15(3):576. <https://doi.org/10.3390/nu15030576>

European Association for the Study of the Liver. EASL clinical practice guidelines on sclerosing cholangitis. *J Hepatol*. 2022;77(3):761-806.

<https://doi.org/10.1016/j.jhep.2022.05.011>

Fung, B. M., & Tabibian, J. H. (2019). Biliary endoscopy in the management of primary sclerosing cholangitis and its complications. *Liver research (Beijing, China)*, 3(2), 106–117. <https://doi.org/10.1016/j.livres.2019.03.004>

Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. *Lancet*. 2013;382(9904):1587-1599. [https://doi.org/10.1016/S0140-6736\(13\)60096-3](https://doi.org/10.1016/S0140-6736(13)60096-3)

Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, DeCook AC, Enders F, Lindor KD. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. *Aliment Pharmacol Ther*. 2011;34(10):1185-1192. <https://doi.org/10.1111/j.1365-2036.2011.04863.x>

Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis – a comprehensive review. *J Hepatol*. 2017;67(6):1298-1323.

<https://doi.org/10.1016/j.jhep.2017.07.022>

Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. *N Engl J Med*. 2016;375(12):1161-1170. <https://doi.org/10.1056/NEJMra1506330>

Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. *Hepatology*. 2009;50(3):808-814.

<https://doi.org/10.1002/hep.23082>

Montano-Loza AJ, Corpechot C, Burra P, Schramm C, Selzner N, Ronca V, Oo YH. Recurrence of autoimmune liver diseases after liver transplantation: review and expert opinion statement. *Liver Transpl*. 2025;31(3):369-383.

<https://doi.org/10.1097/LVT.0000000000000419>

Ponsioen CY, Assis DN, Boberg KM, Bowlus CL, Deneau M, Thorburn D, Aabakken L, Färkkilä M, Petersen B, Rupp C, Hübscher SG; PSC Study Group. Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group consensus process. *Gastroenterology*. 2021;161(6):1764-1775.e5.

<https://doi.org/10.1053/j.gastro.2021.07.046>

Primary sclerosing cholangitis. *Nat Rev Dis Primers*. 2025;11(1):18.

<https://doi.org/10.1038/s41572-025-00606-5>

Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. *Gastroenterology*. 2017;152(8):1975-1984.e8.

<https://doi.org/10.1053/j.gastro.2017.02.038>

## Supplementary Resources

### Differentiating IgG4-Related Sclerosing Cholangitis (IgG4-SC) from Primary Sclerosing Cholangitis (PSC)

The detection of serum immunoglobulin-4 (IgG4) levels as part of the initial evaluation of PSC is recommended to rule out the diagnosis of IgG4-related sclerosing cholangitis, for which corticosteroid treatment is beneficial, in contrast to PSC.

Serum IgG4 levels are elevated in up to 15% of patients with PSC, although **IgG4 levels greater than four times the upper limit of normal** have been reported to have 100% specificity for IgG4-related sclerosing cholangitis. Patients with IgG4-related sclerosing cholangitis may have **normal or mildly elevated serum IgG4 levels**, and the diagnosis of IgG4-related disease requires additional detection of **IgG4-positive plasma cells in biliary epithelium or liver biopsies**.

**Table S1: Prognostic scores**

These models utilize common laboratory studies, age and other clinical assessments, including the presence of varices and cholangiography, to classify patients into high-risk and low-risk groups.

**Table 1: Main scores developed to predict the risk of clinical outcomes in PSC**

	Wiesner 1989	Farrant 1991	Broome 1996	Revised Mayo Score 2000	Boberg 2002	Ponsioen 2002	Tischendorf 2007	Amsterdam- Oxford 2017	UK- PSC 2019	PREsTo 2020
Age	Y	Y	Y*	Y	Y*	Y*	Y	Y*	Y	Y(+ PSC duration)
Bilirubin	Y		Y	Y	Y		Y	Y	Y	Y
Albumin				Y	Y		Y	Y	Y	Y
AST				Y				Y		Y
ALP		Y						Y	Y	Y
Hb	Y								Y	Y (+ Na)
Platelets								Y		Y
IBD	Y									
Histology	Y	Y	Y							
Splenomegaly /Hepatomegaly		Y					Y			
Variceal bleed				Y					Y	
Cholangiogram						Y	Y	Y (small vs large)	Y	
Outcome	Death	Liver- related death/ LT	Liver- related death/LT	Death	PSC- related death/LT	Liver- related death/LT	Death/LT	PSC-related death/LT	Death/ LT	Hepatic decomp- ensation